Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2020 Publisher: hameln pharma ltd, Nexus, Gloucester Business Park, Gloucester, GL3 4AG, UK
ThySat 65 mg tablets.
| Pharmaceutical Form |
|---|
|
Tablet. The tablets are white to yellowish slightly marbled round tablets, with a smooth surface without any defects, cross-scored for ease of breaking. The tablet can be divided into equal quarters. |
Each tablet contains 65.00 mg potassium iodide equivalent to 50.00 mg iodine.
For a full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Potassium iodide |
Potassium iodide is indicated as a thyroid-blocking agent to prevent the uptake of radioactive iodine, for example after a nuclear accident or during a nuclear medicine investigation before administering a radioiodinated compound, which is metabolised to iodide or which contains radioiodine impurities. |
| List of Excipients |
|---|
|
Cellulose, microcrystalline |
Blister (white, opaque PVC/PVDC foil / Al foil with printing), package insert leaflet, outer paper folder.
Size of packing: 4, 10 or 100 tablets.
Not all pack sizes may be marketed.
hameln pharma ltd, Nexus, Gloucester Business Park, Gloucester, GL3 4AG, UK
PL 01502/0082
Date of first authorisation: 25/11/2011
| Drug | Countries | |
|---|---|---|
| THYSAT | United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
